Ohtuvayre denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Ohtuvayre as Experimental or Investigational

Ohtuvayre (ensifentrine) received FDA approval for the maintenance treatment of COPD in 2024, making it the first in its mechanistic class approved for this indication. Despite its FDA approval, Aetna may issue an experimental or investigational denial when the drug is newly approved and has not yet been added to Aetna's internal formulary or clinical policy, or when Aetna's policy applies additional evidence requirements beyond FDA approval itself.

For a drug with a current FDA approval for the specific indication being requested, an experimental/investigational denial is highly anomalous and generally overturnable. FDA approval is the primary federal evidence standard; Aetna's internal evidence criteria cannot simply override a valid approval.

## Why This Is Appealable

An insurer cannot categorically deny an FDA-approved drug on experimental grounds for its approved indication without a specific clinical basis. If your prescriber is requesting Ohtuvayre for COPD maintenance — its approved indication — Aetna's denial conflicts with the FDA's own determination of safety and efficacy. Even if Aetna's formulary has not yet been updated to reflect the approval, you have the right to a formulary exception and to an appeal on medical-necessity grounds.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your EOB. Attach the FDA approval letter or the current FDA-approved prescribing label as Exhibit A. Explicitly state the approved indication and note that your prescriber is requesting Ohtuvayre within its FDA-approved use.
• External review (ACA §2719): After a final internal denial, an independent IRO will review whether the experimental designation is justified for an FDA-approved drug. Standard window is approximately four months; expedited review is available for urgent situations.
• ERISA §503 (employer plans): Request the specific evidence criteria Aetna applied and the reviewing clinician's specialty — it should be pulmonology or internal medicine.

## Documentation to Gather

1. FDA approval documentation — print the current Ohtuvayre (ensifentrine) prescribing label from DailyMed (dailymed.nlm.nih.gov) or the FDA website; this is your primary exhibit. 2. COPD diagnosis confirmation — pulmonary function testing results, clinical diagnosis documentation, and current COPD severity per the chart. 3. Current therapy and its limitations — clinic notes documenting inadequate control, exacerbations, or symptom burden on existing treatments. 4. Prescriber medical-necessity letter — a letter from the prescribing pulmonologist confirming that Ohtuvayre is being requested for its FDA-approved COPD maintenance indication and explaining the clinical rationale. 5. Aetna's experimental/investigational policy — request the written policy to identify whether it carves out FDA-approved drugs; use their own language in your rebuttal.

## Criteria-Mapping Structure

Identify every criterion in Aetna's experimental/investigational policy. For each criterion, provide the counterevidence: FDA approval status, the prescribing label citation, the prescriber's letter, and the clinical records. Submit as a structured point-by-point rebuttal with clearly labeled exhibits. Emphasize that FDA approval for the requested indication is the definitive response to an experimental denial.